• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cybin Inc. - Common Stock (NQ:HELP)

    7.600 -0.100 (-1.30%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 860,711
    Open 7.550
    Bid (Size) 7.450 (100)
    Ask (Size) 7.690 (100)
    Prev. Close 7.700
    Today's Range 7.340 - 7.660
    52wk Range 3.760 - 8.970
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Completes Enrollment in Phase 3 Depression Study
    Via Investor Brand Network
    Topics Intellectual Property
    News headline image
    Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
    EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence

    Performance

    YTD
    -1.7%
    -1.7%
    1 Month
    +10.5%
    +10.5%
    3 Month
    +40.7%
    +40.7%
    6 Month
    +3.7%
    +3.7%
    1 Year
    -1.7%
    -1.7%

    More News

    Read More
    News headline image
    Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
    Via FinancialNewsMedia
    News headline image
    Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
    From Helus Pharma
    Via GlobeNewswire
    News headline image
    Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
    Via FinancialNewsMedia
    News headline image
    Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
    From MarketNewsUpdates.com
    Via GlobeNewswire
    NetworkNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal 2026 Results, Highlights Phase 3 Progress
    Via Investor Brand Network
    News headline image
    Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
    From Helus Pharma
    Via GlobeNewswire
    MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Closes $50 Million Public Offering
    Via Investor Brand Network
    News headline image
    Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
    From Helus Pharma
    Via GlobeNewswire
    InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Prices $50 Million Public Offering
    Via Investor Brand Network
    BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Surpasses 86% Enrollment in Phase 3 APPROACH Trial
    Via Investor Brand Network
    News headline image
    FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
    Via FinancialNewsMedia
    News headline image
    Helus Pharma™ Announces US$50 Million Underwritten Offering
    From Helus Pharma
    Via GlobeNewswire
    News headline image
    Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
    From Helus Pharma
    Via GlobeNewswire
    MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Chief Medical Officer to Participate in H.C. Wainwright Neuro Perspectives Conference
    Via Investor Brand Network
    News headline image
    Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
    From Helus Pharma
    Via GlobeNewswire
    BioMedNewsBreaks — Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) to Participate in Jefferies Global Healthcare Conference
    Via Investor Brand Network
    News headline image
    Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
    From Helus Pharma
    Via GlobeNewswire
    InvestorNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Issues Correction To TARA Mind Partnership Announcement
    Via Investor Brand Network
    News headline image
    CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
    From Helus Pharma
    Via GlobeNewswire
    News headline image
    Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
    From Helus Pharma
    Via GlobeNewswire
    MissionIRNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Partners With TARA Mind to Support Phase 3 Trial Recruitment in Veterans
    Via Investor Brand Network
    News headline image
    Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
    From Helus Pharma
    Via GlobeNewswire
    BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Adds Robert Langer, Stephen Brannan To Scientific Advisory Board
    Via Investor Brand Network

    Frequently Asked Questions

    Is Cybin Inc. - Common Stock publicly traded?
    Yes, Cybin Inc. - Common Stock is publicly traded.
    What exchange does Cybin Inc. - Common Stock trade on?
    Cybin Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Cybin Inc. - Common Stock?
    The ticker symbol for Cybin Inc. - Common Stock is HELP on the Nasdaq Stock Market
    What is the current price of Cybin Inc. - Common Stock?
    The current price of Cybin Inc. - Common Stock is 7.600
    When was Cybin Inc. - Common Stock last traded?
    The last trade of Cybin Inc. - Common Stock was at 07/28/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.